-

908 Devices to Participate in Investor Conferences in March

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today announced it will participate in the following investor conferences.

  • TD Cowen 46th Annual Healthcare Conference, Boston, MA
    Fireside chat on Wednesday, March 4 at 9:10 a.m. Eastern Time
  • Leerink Global Healthcare Conference, Miami, FL
    Fireside chat on Monday, March 9 at 1:40 p.m. Eastern Time

Interested parties may access a live and archived webcast of these sessions on the “Investors” section of the company website at: www.908devices.com.

About 908 Devices
908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers in vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learning. For more information, visit www.908devices.com.

Contacts

IR & Media
Barbara Russo
IR@908devices.com

Industry:

908 Devices

NASDAQ:MASS
Release Versions
English

Contacts

IR & Media
Barbara Russo
IR@908devices.com

More News From 908 Devices

908 Devices Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Outlook

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2026. “We delivered a strong start to 2026, achieving 14% revenue growth and meaningful margin expansion,” said Kevin J. Knopp, CEO and Co-founder. “We are also excited to announce the acquisition of NIRLAB AG, a strate...

908 Devices Acquires NIRLAB AG, Expanding Its Narcotics Detection Portfolio

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has completed the acquisition of NIRLAB AG, a privately held company based in Lausanne, Switzerland. The company delivers AI-powered, cloud-connected near-infrared (NIR) spectroscopy to perform handheld chemical analysis of narcotics in seconds. This acquisition expands 908 Devices' analytical portfolio and strengthens its leadership in narcot...

908 Devices to Report First Quarter 2026 Financial Results on May 6, 2026

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the first quarter 2026 before market open on Wednesday, May 6, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “Investors” sect...
Back to Newsroom